NC-LENOVO
28.2.2024 15:01:36 CET | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY) is rolling out a new solution to help customers extend the lifecycle of their devices with cost-efficient IT choices for a more sustainable future. Through Lenovo Certified Refurbished, organizations can deploy refurbished PCs that cater to their different computing needs and help manage their IT carbon footprint. Lenovo TruScale Device as a Service (DaaS) customers will also have more options to optimize their IT mix according to their unique economic and business needs, and with circularity in mind. Only Lenovo and accredited partners will offer the Lenovo certification, guaranteeing industry-leading quality devices that businesses can depend on.
“Environmental sustainability is a leading concern for businesses of every size, in every sector,” said Claudia Contreras, Executive Director of Global Sustainability Services for Lenovo. “Lenovo Certified Refurbished extends the lifecycle of our technology to improve ROI and help reduce waste, offering a solution that provides customers a purchase option to help support a more sustainable future. Certified Refurbished will help reduce e-waste, give devices new life, and positively contribute to the circular economy.”
Refurbishment, reuse, and recycling are key concepts in the circular economy, a resource and consumption system that helps mitigate waste. Lenovo is committed to implementing circular practices at every stage of the IT lifecycle, and as a leading global PC manufacturer, is uniquely qualified to help customers meet sustainability goals and embrace the benefits of circularity with confidence. Through the Lenovo 360 Circle community, channel partners are also aligned with collaborative actions to drive circular outcomes for customers and build a more sustainable future.
Lenovo’s 2023 Global Study of CIOs found that 60% of CIOs are turning towards as a Service (aaS) offerings for their tech stacks, including for sustainability management, and 62% said they find it challenging for their organization to reach sustainability goals. Outcome-based consumption models like Lenovo TruScale DaaS help businesses efficiently manage services, cost reduction, and waste reduction through a single source with the flexibility to scale as needed.
“Along with unified program management and streamlined financing, Lenovo TruScale DaaS offers lifecycle transformation approaches – including IT carbon footprint management and e-waste reduction – that help drive circularity and move customers closer to their sustainability goals while also helping to improve productivity and cost considerations. We’re excited to extend TruScale DaaS benefits to include options like Lenovo Certified Refurbished and help make IT circularity more achievable for customers,” said Anupam Garg, Lenovo Digital Workplace Solutions Offering Development leader.
Lenovo Certified Refurbished PCs undergo comprehensive data sanitization; expert testing to meet Lenovo’s high quality, security, and performance standards; and transparent, consistent quality grading. Access to Lenovo’s global support network provides added assurance that there is no compromise on security safeguards or PC performance, and that the refurbished devices will have a productive operational life with up to three years of standard warranty (with the option to upgrade). Lenovo Certified Refurbished PCs can help customers lower technology outlays while retaining a high level of performance and functionality, and refurbished devices may open a wider pool of options for budget-conscious organizations.
Lenovo Certified Refurbished PCs will be available initially in Denmark, France, Germany, and the U.K., with a planned global rollout. Lenovo Certified Refurbished is the latest in a series of Lenovo offerings that aid customers in their sustainability journeys. Learn more about Lenovo’s Sustainability Solutions.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
LENOVO and TRUSCALE are trademarks of Lenovo. ©2024 Lenovo. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228104727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom